Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | RNASEL | Q05823 | 10/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22399216 | 0.92 | RNASEL (0.66) | RNASEL | |
| SCHEMBL22399401 | 0.92 | RNASEL (0.66) | RNASEL | |
| SCHEMBL24499705 | 0.91 | CA5A (0.64) | CA5ARNASELTGM2NT5ELMNA | |
| SCHEMBL18510923 | 0.91 | CA5A (0.64) | CA5ARNASELTGM2NT5ELMNA | |
| SCHEMBL21942697 | 0.89 | CA5A (0.63) | CA5ARNASELTGM2NT5E | |
| SCHEMBL22399219 | 0.88 | RNASEL (0.53) | RNASELTGM2NT5E | |
| SCHEMBL21942777 | 0.88 | RNASEL (0.55) | RNASELTGM2 | |
| SCHEMBL21539231 | 0.88 | RNASEL (0.60) | RNASELTGM2 | |
| SCHEMBL22381843 | 0.88 | RNASEL (0.57) | RNASELTGM2NT5E | |
| SCHEMBL22399660 | 0.88 | RNASEL (0.57) | RNASELTGM2NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | CA5A 2818/4885RNASEL 574/4885TGM2 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.